Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin)

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Circulation

• Publication date

  2013-11-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.113.004406PMID 24243886PMCID PMC3946056
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Effect of a monoclonal antibody to PCSK9 on LDL cholesterol].

  2012cited by this paper
• On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).

  2012cited by this paper
• The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

  2012cited by this paper
• On-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy: JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)

  2012influential reference
• Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.

  2012cited by this paper
• Lipid-related markers and cardiovascular disease prediction.

  2012cited by this paper
• Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

  2012cited by this paper
• Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies.

  2012influential reference
• Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

  2012cited by this paper
• Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects: The Atherosclerosis Risk in Communities (ARIC) Study

  2011cited by this paper
• Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice.

  2011cited by this paper
• Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

  2011cited by this paper
• Lipoprotein(a) as a cardiovascular risk factor: current status

  2010cited by this paper
• Lipoprotein(a) and risk of type 2 diabetes.

  2010cited by this paper
• Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.

  2010cited by this paper
• HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.

  2010cited by this paper
• Safety of anacetrapib in patients with or at high risk for coronary heart disease.

  2010cited by this paper
• Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

  2009influential reference
• Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

  2009cited by this paper
• Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.

  2009influential reference
• A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM.

  2009cited by this paper
• Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity

  2009cited by this paper
• Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

  2009cited by this paper
• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

  2008cited by this paper
• Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women.

  2006cited by this paper
• Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions.

  2003cited by this paper
• Serum Lipoprotein(a) Level and its Clinical Significance in Patients with Systemic Lupus Erythematosus

  2002cited by this paper
• Is lipoprotein(a)-cholesterol a better predictor of vascular disease events than total lipoprotein(a) mass? A nested case control study from the West of Scotland Coronary Prevention Study.

  2000influential reference
• Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study

  1997cited by this paper
• Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a).

  1995cited by this paper
• The Clinical Perspective

  1994cited by this paper
• Apolipoprotein(a) size heterogeneity is related to variable number of repeat sequences in its mRNA.

  1990cited by this paper
• Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid

  1989cited by this paper
• Transient changes of serum lipoprotein(a) as an acute phase protein.

  1989cited by this paper
• A New Serum Type System in Man — The Ld System

  1965cited by this paper

• Diagnostic and Severity Assessment of Coronary Artery Disease Using ApoB/ApoA-I Ratio: Insights from a Statin-Treated Eastern European Cohort.

  2026cites this paper
• Machine learning to predict elevated lipoprotein(a).

  2026cites this paper
• Case Report: Elevated Lp(a) as a cause of severe ASCVD in a healthy veteran athlete with low calculated QRISK3 score

  2026cites this paper
• Overview of the Study of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease

  2026cites this paper
• Lipoprotein(a) Is Associated With Increased Risk of Abdominal Aortic Aneurysm

  2026cites this paper
• Lipoprotein(a) levels in a sample of 115,197 subjects from the largest Brazilian private laboratory

  2025cites this paper
• Value of lipoprotein(a) in predicting severity of coronary artery stenosis in patients with chronic coronary artery disease: a cross-sectional study in Vietnam

  2025cites this paper
• Interaction Between Lipoprotein(a) and Other Lipid Molecules: A Review of the Current Literature

  2025cites this paper
• Statins—Their Effect on Lipoprotein(a) Levels

  2025cites this paper
• Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.

  2025cites this paper
• The interactions of Lipoprotein(a) with common cardiovascular risk factors in cardiovascular disease risk: evidence based on the UK Biobank

  2025influential citation
• Lipoproteins predicting coronary lesion complexity in premature coronary artery disease: a supervised machine learning approach

  2025cites this paper
• Treatment of severe hyperlipidemia and associated cardiovascular outcomes: Data from a large healthcare system.

  2025cites this paper
• Lp(a): A clinical review.

  2025cites this paper
• Clinical Response to Elevated Lipoprotein(a): Practical Approach for Risk Management in the Absence of Targeted Therapies

  2025cites this paper
• Pharmacokinetics and Safety of Pelacarsen, a GalNAc3 ‐Conjugated Antisense Oligonucleotide Targeting Apo(a), in Participants With Mild Hepatic Impairment

  2025cites this paper
• Lipoprotein(a) at a “Tipping Point”: case to move to universal screening

  2025cites this paper
• Novel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse Cohort

  2025cites this paper
• Clinical significance of lipoprotein(a) as a residual risk factor for atherosclerotic coronary plaque progression in statin-treated patients with coronary artery disease

  2025cites this paper
• Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease in South Asian Individuals.

  2025cites this paper
• The Effect of Low, Moderate, and High Doses of Rosuvastatin on Lipoprotein(a) Levels in Hyperlipidemic Patients with Impaired Fasting Glucose: A Post-Hoc Analysis.

  2025cites this paper
• Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications

  2025cites this paper
• Association of Lp(a) With Stroke and Cerebral Injury on MRI: Insights From the HCHS/SOL (Hispanic Community Health Study/Study of Latinos) and Investigation of Neurocognitive Aging MRI (SOL-INCA MRI)

  2025cites this paper
• Periodontitis Progression During Cardiac Rehabilitation After Acute Coronary Syndrome: Cohort Study

  2025cites this paper
• Lipoprotein(a) and Cardiovascular Risk in Asian Populations: A Comprehensive Review

  2025cites this paper
• Is Targeting LDL-C Levels Below 70 mg/dL Beneficial for Cardiovascular and Overall Health? A Critical Examination of the Evidence

  2025cites this paper
• Lipoprotein(a) and Its Role in Peripheral Arterial Disease: A Narrative Review

  2025cites this paper
• Fuelling aortic stenosis: the integral role of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3-mediated glycolysis in Lp(a)-induced valve inflammation

  2025cites this paper
• Serum lipoprotein(a) concentrations in presumably healthy Polish subjects in relation to age, sex, and cardiometabolic risk factors

  2025cites this paper
• Differential impact of lipoprotein(a) on subclinical coronary atherosclerosis in asymptomatic individuals with and without diabetes mellitus

  2025cites this paper
• Lipoprotein(a) and High-Risk Coronary Plaques: Mechanisms, Characteristics, and Emerging Therapeutic Strategies

  2025cites this paper
• Lipoprotein(a) in acute coronary syndrome patients: A cross-sectional study

  2025cites this paper
• Additive effects of Lp(a) and inflammation on cardiovascular risk beyond LDL-C lowering: circulating and genetic evidence from 401,548 adults.

  2025cites this paper
• Long-term lipoprotein and lipid profiles and association with metabolic risk markers in youth with perinatally acquired HIV and matched controls: a 10-year comparative cohort study

  2025cites this paper
• Contemporary and Emerging Therapeutics in Cardiovascular-Kidney-Metabolic (CKM) Syndrome: In Memory of Professor Akira Endo

  2025cites this paper
• Lipoprotein(a): structural basis, bidirectional risk, and therapeutic frontiers

  2025cites this paper
• Evolving strategies in cardiovascular disease prevention: 2025 American society for preventive cardiology highlights

  2025cites this paper
• Application of ES-DMA-CPC for Comprehensive Molecular Profiling in Hemodialysis: A Focus on β2-Microglobulin

  2025cites this paper
• Lipoprotein(a) - From Biomarker to Therapy: A Review for the Clinician.

  2025cites this paper
• Does statin matter when it comes to Lipoprotein(a) levels?

  2025cites this paper
• Therapeutic advances in the Lp(a) battle: what do we know and what are the most awaited novelties in the field?

  2025cites this paper
• Assessment of the Utilization of Lipoprotein (a) and its Relationship with Cardiovascular Outcomes: A Retrospective Cohort Study from a Public Hospital in New York City

  2025cites this paper
• Reply to: "Does statin matter when it comes to Lipoprotein(a) levels?"

  2025cites this paper
• Pelacarsen: Mechanism of action and Lp(a)-lowering effect.

  2025cites this paper
• The Effect of Lipoprotein(a) Levels on Non‐Culprit Atherosclerosis in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention: An Optical Coherence Tomography Study

  2025cites this paper
• The Role of Lipoprotein(a) in Peripheral Artery Disease

  2024cites this paper
• Effects of saturated fatty acid consumption on lipoprotein(a): a systematic review and meta-analysis of randomized controlled trials.

  2024cites this paper
• Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review

  2024cites this paper
• Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry

  2024cites this paper
• Development and multinational validation of an algorithmic strategy for high Lp(a) screening

  2024cites this paper
• Sex-based utilization of guideline recommended statin therapy and cardiovascular disease outcomes: Data from a multisite healthcare network primary prevention cohort

  2024cites this paper
• Association of lipoprotein(a) with progression of coronary artery calcification: retrospective longitudinal study

  2024cites this paper
• Effects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease: A Pooled Analysis of the ORION-10 and ORION-11 Randomized Trials.

  2024cites this paper
• Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.

  2024cites this paper
• Variation in lipoprotein(a) response to potent lipid lowering: The role of apolipoprotein (a) isoform size.

  2024cites this paper
• Detailed Lipid Profiles and Lipid-related Residual Risk after 12-week 10 mg Rosuvastatin Treatment for Acute Myocardial Infarction

  2024cites this paper
• Lipoprotein (a) in the Full Spectrum of MASLD; Evidence from Histologically and Genetically Characterized Cohorts.

  2024cites this paper
• Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?

  2024cites this paper
• Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan areas of Brandenburg, Germany

  2024cites this paper
• Espoirs et place prochaine potentielle des inhibiteurs de la Lp(a)

  2024cites this paper
• Lipoprotein (a): Underrecognized Risk with a Promising Future

  2024cites this paper
• Lipoprotein(a): Emerging insights and therapeutics

  2024cites this paper
• Novel Therapeutic Approaches for the Management of Elevated Lipoprotein(a): From Traditional Agents to Future Treatment Options

  2024cites this paper
• A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.

  2024influential citation
• Progress in pediatric cardiology VSI: Cardiovascular disease in pediatrics lipoprotein(a) in atherosclerotic cardiovascular disease, type 2 diabetes, and liver disease

  2024cites this paper
• Traditional Risk Factors, Optimal Cardiovascular Health, and Elevated Lipoprotein(a).

  2024cites this paper
• Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis

  2024cites this paper
• Prognostic role of lipoprotein(a) in atherosclerotic cardiovascular disease risk from a perspective on current risk stratification

  2024cites this paper
• One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial

  2024cites this paper
• Role of Lipoprotein (A) in aortic valve stenosis: Novel disease mechanisms and emerging pharmacotherapeutic approaches

  2024cites this paper
• Dyslipidemia: A Narrative Review on Pharmacotherapy

  2024cites this paper
• Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab

  2024cites this paper
• Advantages of using Genetically Elevated Lipoprotein(a) Levels in Predicting 5-Year Major Adverse Cardiovascular Events Relating to Coronary Artery Disease in Women

  2024cites this paper
• Efficacy of Traditional Anti-lipidemic Drugs in Lowering Lipoprotein(a) Levels: A Systematic Review

  2024cites this paper
• Confounding Factors Responsible for Elevated Lp(a) Levels in Patients with Coronary Artery Disease

  2024cites this paper
• Advances in Pharmacological Approaches for Managing Hypercholesterolemia: A Comprehensive Overview of Novel Treatments

  2024cites this paper
• The Association of Lipoprotein(a) and Coronary Artery Calcium in Asymptomatic Patients: A Systematic Review and Meta-analysis.

  2024cites this paper
• A novel method for predicting Lp(a) levels from routine outpatient genomic testing identifies those at risk of cardiovascular disease across a diverse cohort

  2024influential citation
• High lipoprotein(a) is a risk factor for peripheral artery disease, abdominal aortic aneurysms, and major adverse limb events

  2024cites this paper
• Olpasiran Pharmacodynamic Study: Ensuring We Go a Mile Deep But More Than an Inch Wide.

  2024cites this paper
• Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities

  2024influential citation
• Lipoprotein(a) in atherosclerotic cardiovascular disease and proprotein convertase subtilisin/kexin-type 9 inhibitors.

  2024cites this paper
• Strategies for management of patients with elevated lipoprotein(a)

  2024cites this paper
• Plasma Biomarker Profiles for Premature and Nonpremature Coronary Heart Disease in Women.

  2024cites this paper
• Lp(a): A Rapidly Evolving Therapeutic Landscape

  2024cites this paper
• Lipoprotein(a) as a Higher Residual Risk for Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus than without

  2023cites this paper
• Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia

  2023cites this paper
• Plasminogen Receptors Promote Lipoprotein(a) Uptake by Enhancing Surface Binding and Facilitating Macropinocytosis

  2023cites this paper
• Assessment of cardiovascular disease risk: a 2023 update

  2023cites this paper
• The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies.

  2023cites this paper
• Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)

  2023cites this paper
• Risk factors, lab parameters, angiographic characteristics and outcomes of coronary artery disease in young South Asian patients: a systematic review

  2023cites this paper
• Lipoprotein(a) in clinical practice: A guide for the clinician.

  2023cites this paper
• Combined effect of D-dimer, hs-CRP, and Lp(a) on 5-year clinical outcomes after percutaneous coronary intervention: A large real-world study in China

  2023cites this paper
• Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study.

  2023cites this paper
• LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics.

  2023cites this paper
• Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials.

  2023cites this paper
• Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention

  2023cites this paper
• Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives

  2023cites this paper
• Approach to the Patient with a Suboptimal Statin Response: Causes and Algorithm for Clinical Management.

  2023cites this paper